PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/109764

Please be advised that this information was generated on 2018-01-15 and may be subject to change.
The Calcium Sensitizer Levosimendan Improves Human Diaphragm Function

Jonne Doorduin1, Christer A. Sinderby2,3, Jennifer Beck1,4, Dick F. Stegeman5,6, Hieronymus W. H. van Hees7, Johannes G. van der Hoeven1, and Leo M. A. Heunks1

1Department of Critical Care Medicine, Radboud University Nijmegen Medical Centre, The Netherlands; 2Department of Medicine, Division of Critical Care Medicine, University of Toronto; 3Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, University of Toronto; 4Department of Pediatrics, St. Michael’s Hospital, University of Toronto, Toronto, Canada; 5Department of Neurology, Radboud University Nijmegen Medical Centre, The Netherlands; 6Faculty of Human Movement Sciences, Research Institute MOVE, VU University, Amsterdam, The Netherlands; and 7Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Internet address: www.atsjournals.org

© 2012 by the American Thoracic Society

Rationale: Acquired diaphragm muscle weakness is a key feature in several chronic conditions, including chronic obstructive pulmonary disease, congestive heart failure, and difficult weaning from mechanical ventilation. No drugs are available to improve respiratory muscle function in these patients. Recently, we have shown that the calcium sensitizer levosimendan enhances the force-generating capacity of isolated diaphragm fibers.

Objectives: To investigate the effects of the calcium sensitizer levosimendan on in vivo human diaphragm function.

Methods: In a double-blind, randomized, crossover design, 30 healthy subjects performed two identical inspiratory loading tasks. After the first loading task, subjects received levosimendan (40 µg/kg bolus followed by 0.1/0.2 µg/kg/min continuous infusion) or placebo. Transdiaphragmatic pressure, diaphragm electrical activity, and their relationship (neuromechanical efficiency) were measured during loading. Magnetic phrenic nerve stimulation was performed before the first loading task and after bolus administration to assess twitch contractility. Center frequency of diaphragm electrical activity was evaluated to study the effects of levosimendan on muscle fiber conduction velocity.

Measurements and Main Results: The placebo group showed a 9% (P = 0.01) loss of twitch contractility after loaded breathing, whereas no loss in contractility was observed in the levosimendan group. Neuromechanical efficiency of the diaphragm during loading improved by 21% (P < 0.05) in the levosimendan group. Baseline center frequency of diaphragm electrical activity was reduced after levosimendan administration (P < 0.05).

Conclusions: The calcium sensitizer levosimendan improves neuromechanical efficiency and contractile function of the human diaphragm. Our findings suggest a new therapeutic approach to improve respiratory muscle function in patients with respiratory failure.

Keywords: diaphragm; muscle weakness; calcium sensitization; levosimendan

Impaired force generation of the respiratory muscles has been recognized in a variety of diseases, including chronic obstructive pulmonary disease (COPD) and congestive heart failure, and in critically ill patients (1–7). The pathophysiological substrate of diaphragm dysfunction in these disorders is multifactorial and includes muscle fiber atrophy and contractile protein dysfunction (3, 8–11). We found that diaphragm muscle fibers of patients with COPD display reduced sensitivity of the contractile proteins to calcium (9, 12). In other words, more calcium is needed to develop the same amount of force as in the non-COPD diaphragm, resulting in impaired contractile efficiency of the diaphragm muscle. Subsequent studies have shown that calcium sensitivity is also reduced in the diaphragm of animal models of congestive heart failure and prolonged mechanical ventilation (2, 13). Despite a better understanding of respiratory muscle dysfunction in chronic diseases, no drug is available to improve respiratory muscle function in humans.

Levosimendan is a clinically used calcium sensitizer that has been approved to enhance cardiac contractility in patients with acute heart failure. Clinical studies have shown that levosimendan improves cardiac function in these patients (14). Levosimendan enhances the binding of calcium to troponin C, thereby improving the responsiveness of myofilaments to calcium. Accordingly, a greater amount of force is generated for the same level of cytosolic calcium, resulting in enhanced contractile efficiency. Levosimendan has vasodilatory properties mediated by the opening of the ATP-sensitive potassium (K ATP) channels (15).

Recently, we have shown that levosimendan enhances calcium sensitivity of permeabilized muscle fibers obtained from the human diaphragm, including patients with COPD (12). However, the effects of calcium sensitizing on the human diaphragm in vivo have not been studied. Based on our in vitro data (12), we
hypothesize that levosimendan improves contractile function of the human diaphragm in vivo through calcium sensitizing and that levosimendan would decrease muscle fiber conduction velocity of the diaphragm through its effects on $K_{ATP}$ channels in diaphragm fibers. We tested this hypothesis in a double-blind, placebo-controlled, crossover design in healthy subjects performing inspiratory loading tasks. Some of the results of this study have been previously reported in the form of an abstract (16).

**METHODS**

We enrolled 30 healthy volunteers in this trial. The protocol was approved by the ethical committee of the Radboud University Nijmegen Medical Centre and registered at ClinicalTrials.gov (NCT01101620). All subjects gave their informed consent.

**Esophageal Catheter**

Diaphragm electromyographic activity (EMGdi), esophageal pressure (Pes), and gastric pressure (Pga) were obtained with a multielectrode esophageal catheter with two balloons (details are provided in the online supplement). Transdiaphragmatic pressure (Pdi) was calculated as $P_{ga} - P_{es}$.

**Magnetic Stimulation and Maximal Inspiratory Effort**

Cervical magnetic stimulation of the phrenic nerves was performed to measure twitch Pdi ($P_{dитw}$) and compound muscle action potential of the diaphragm ($CMAP_{dит}$). Details about the stimulation protocol are provided in the online supplement.

Maximal voluntary Pdi ($P_{dимакс}$) was measured as mean Pdi in the first second during a maximal inspiratory effort against a closed valve at functional residual capacity.

**Inspiratory Loading Task**

Each subject performed two identical loading tasks, one before and one after administration of the study medication. Sitting in upright position with uncast abdomen, subjects breathed through a mouthpiece while wearing a nose clip. Subjects performed intermittent inspiratory maneuvers of 10 seconds against a closed valve (near-isometric contractions) followed by 7 seconds of unloaded breathing. Duty cycle was imposed by a sound signal, and subjects were asked to target 40% of $P_{dимакс}$. Visual feedback of Pdi was provided. Total loading task duration was 10 minutes. During loading, EMGdi and Pdi were recorded continuously, as well as in unloaded conditions approximately 5 minutes before and after loading. Respiratory effort sensation was scored with a Borg scale (range, 0–20) at 1, 3, 6, and 9 minutes into loading.

**Experimental Protocol**

The protocol is presented in Figure 1. $P_{dимакс}$ and $P_{dитw}$ were measured and followed by the first loading task and 30 minutes of unloaded breathing. After randomization, subjects received levosimendan bolus (40 g/kg bodyweight, intravenously) or an equal volume of placebo in 10 minutes. $P_{dимакс}$ and $P_{dитw}$ measurements were repeated and followed by 30 minutes of continuous levosimendan (0.1 g/kg bodyweight/min, intravenously) or placebo infusion. A second loading task was performed while infusing levosimendan (0.2 g/kg/min, intravenously) or placebo.

Heart rate, end tidal carbon dioxide (etCO$_2$), and peripheral oxygen saturation ($Sp_{O2}$) were monitored continuously. Blood pressure was measured noninvasively every 10 minutes and during bolus administration each minute. In six subjects, cardiac output was determined by transthoracic echocardiography directly before and after bolus administration.

**Data Analysis and Statistics**

Measurement variables were analyzed offline in Matlab R2009b (The Mathworks, Natick, MA) (details are provided in the online supplement). The ratio of mean inspiratory Pdi and EMGdi amplitude was calculated as a measure of the neuromechanical efficiency of the diaphragm. Changes in muscle fiber conduction velocity were evaluated using the power spectrum center frequency (CFdi) of the EMGdi (details are provided in the online supplement). Comparisons were made with the appropriate t test. Changes over time during loaded breathing were analyzed using repeated measures ANOVA. Values are means ± SEM, and $P < 0.05$ was considered significant. Statistical analyses were performed with SPSS 16.0 (SPSS, Chicago, IL).

**RESULTS**

Baseline characteristics of the subjects (male/female, 23/7; age, 22 ± 0.4 yr; bodyweight, 74 ± 1 kg; and body mass index, 23 ± 0.4 kg/m$^2$) were not different between the placebo and levosimendan groups. All subjects (n = 30) received study medication as dictated by the protocol. One subject was excluded due to technical problems with the esophageal catheter. Two subjects were not able to maintain targeted Pdi (< 30% of $P_{dимакс}$) during the first loading task and were excluded from data analysis. The remaining subjects (placebo, n = 13; levosimendan, n = 14) were able to keep their targeted Pdi during both loading tasks (44 ± 1% and 43 ± 2%), indicating compliance to the protocol. $Sp_{O2}$ was above 96% in all subjects during the study; no supplemental oxygen was given. There were no differences in etCO$_2$ between the placebo and levosimendan group during loaded breathing.

Furthermore, there were no serious adverse events during the experimental protocol. One subject, receiving levosimendan, experienced a mild degree of nausea after completion of the study.

**Diaphragm Contractility**

Cervical magnetic stimulation of the phrenic nerves resulted in reproducible twitch pressures in all subjects. Data from magnetic stimulation and maximal inspiratory maneuvers, as well as hemodynamic data, are given in Table 1. There was no significant difference in $P_{dитw}$ and $P_{dимакс}$ between the placebo and the levosimendan groups before study medication.

Figure 2 shows a decreased contractile response of the diaphragm after the first loading task in a subject receiving placebo.
On average, loaded breathing in subjects receiving placebo resulted in significant reductions in Pdi_{tw} (−9 ± 3%; \(P = 0.01\)) and Pdi_{max} (−5 ± 3%; \(P < 0.05\)). The group receiving levosimendan after the first period of loaded breathing revealed no significant decrease in Pdi_{tw} and Pdi_{max} (Figure 3; Table 1).

**Neuromechanical Efficiency of the Diaphragm**

In Figure 4, representative tracings of EMG_{di} and Pdi are presented for the first loading task (before study medication) and the second loaded task (with study medication) for both groups. Neuromechanical efficiency of the diaphragm (Pdi/EMG_{di}) in the first loading task was not different between the placebo and the levosimendan groups (both 1.3 ± 0.2 cm H_{2}O/μV) and remained stable throughout the loading task (Figure 5). Neuromechanical efficiency during unloaded breathing and during the second loading task was improved by 21% (\(P < 0.05\), compared with the first loading task) in the levosimendan group, whereas neuromechanical efficiency was not affected in the placebo group (Figure 5). The improved neuromechanical efficiency in subjects receiving levosimendan sustained throughout the entire loading task.

**Center Frequency of Diaphragm Electrical Activity**

During both loaded breathing protocols, CF_{di} decreased over time (\(P < 0.001\)) (see Figure E1 in the online supplement) in both groups. Administration of levosimendan resulted in a downward shift in baseline CF_{di} during the second loaded breathing protocol (\(P < 0.05\); Figure E1), whereas placebo did not affect CF_{di}.

**Respiratory Effort Sensation**

Respiratory effort sensation increased over time (\(P < 0.001\)) during loaded breathing until a score of 16 was reached. Neither levosimendan nor placebo affected respiratory effort sensation.

**DISCUSSION**

The present study is the first to evaluate the effect of the calcium sensitizer levosimendan on human diaphragm function in vivo. In this double-blind, randomized study, an intervention of loaded breathing resulted in significant loss of diaphragm contractility in the placebo group but not in the levosimendan group, suggesting that levosimendan restored diaphragm contractility. Loaded breathing after drug administration was associated with improved neuromechanical efficiency of the diaphragm in the levosimendan group. Furthermore, levosimendan reduced baseline center frequency of diaphragm electrical activity. Levosimendan was well tolerated with negligible side effects.

**Calcium Sensitivity and Muscle Fiber Conduction Velocity: Effects of Levosimendan**

Skeletal muscle force develops as intracellular calcium rises and binds to troponin C, resulting in conformational changes in the troponin complex, allowing interaction between actin and myosin to form force-generating cross-bridges. Reuptake of calcium from the cytoplasm into the sarcoplasmic reticulum is a high energy-consuming process (up to 40% of total energy expenditure). Thus, reduced sensitivity of the troponin complex for calcium requires higher levels of cytoplasmic calcium to generate the same amount of force, requiring higher energy consumption and elevated CO_{2} production.

Levosimendan belongs to a relatively new class of drugs, the calcium sensitizers and is approved in more than 40 countries worldwide to improve cardiac function in patients with acute heart failure (14). Although the loading dose of levosimendan in this study is higher than recommended for the treatment of

---

**TABLE 1. DIAPHRAGM CONTRACTILITY AND HEMODYNAMIC VARIABLES AT BASELINE AND AFTER LOADING + BOLUS ADMINISTRATION**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Placebo (n = 13)</th>
<th>Levosimendan (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After Loading + Bolus Administration</td>
</tr>
<tr>
<td>Pdi_{tw} cm H_{2}O</td>
<td>35 ± 2^1</td>
<td>32 ± 2^1</td>
</tr>
<tr>
<td>Pdi_{max} cm H_{2}O</td>
<td>1.3 ± 0.2</td>
<td>1.3 ± 0.2</td>
</tr>
<tr>
<td>EMG_{di} max μV</td>
<td>130 ± 8</td>
<td>122 ± 7^2</td>
</tr>
<tr>
<td>MAP, mm Hg</td>
<td>76 ± 9</td>
<td>81 ± 10</td>
</tr>
<tr>
<td>HR, bpm</td>
<td>92 ± 2</td>
<td>89 ± 4</td>
</tr>
<tr>
<td>CO_{2} L/min</td>
<td>4.5 ± 1.3</td>
<td>4.6 ± 0.4</td>
</tr>
</tbody>
</table>

**Definition of abbreviations:** CMAP_{di} = compound muscle action potential of the diaphragm; CO = cardiac output; EMG_{di max} = maximum electromyographic activity; MAP = mean arterial pressure; Pdi_{max} = maximum transdiaphragmatic pressure; Pdi_{tw} = twitch transdiaphragmatic pressure; HR = heart rate.

^1 Data are presented as mean ± SEM.

^2 Significantly different from before study medication (\(P < 0.05\)).

^3 MAP, HR, and CO were measured directly before and after bolus administration. CO was measured only in \(n = 2\) (placebo group) and \(n = 4\) (levosimendan group).

---

**Figure 2. (A) The compound muscle action potential of the diaphragm (CMAP_{di}) and (B) twitch transdiaphragmatic pressure (Pdi_{tw}) elicited by cervical magnetic stimulation before (black line) and after the first loading task (blue striped line) in a subject receiving placebo. In response to equal diaphragm activation (i.e., equal CMAP_{di}), there is decreased contractility after loaded breathing. Note the difference in scale of the x axis between panels A and B.**
consistent with previous data by Laghi and colleagues (20). How-

of the CFdi curve during loaded breathing (Figure E1). The

(21). This is in line with the established effects of levosimendan on KATP channel activation (15) and with the finding that extracellular [K+] accumulation contributes to reduced muscle fiber conduction velocity (23, 24). Because administration of levosimendan improves neuromechanical efficiency of the diaphragm by 21%, it is unlikely that extracellular [K+] accumulation results in functional impairment of the dia-

phragm. Moreover, preserving a hyperpolarized sarcolemma by activating KATP channels might play a myoprotective role under conditions of metabolic stress (25).

Enhancing calcium sensitivity with levosimendan appears to be a rational and effective approach to improve respiratory muscle function, in particular in patients with imminent respiratory failure.

Clinical Implications

Reduced force generation of the respiratory muscles has been demonstrated in numerous disorders, including COPD, congestive heart failure, pulmonary hypertension, and patients on mechanical ventilation (1–7). There are no pharmacological interventions available to improve respiratory muscle function.

Aubier and colleagues have previously shown that dopamine (26) and aminophylline (27) improve contractility of the human diaphragm, although the effects of aminophylline are controver-
sial (28). Neither dopamine nor aminophylline has been used in clinical practice to optimize respiratory muscle function, probably due to the small therapeutic window, the risk of severe side effects (aminophylline, dopamine), and the very short half-life (dopa-

mine). Instead, the active levosimendan metabolite OR-1896 has a half-life of 70 to 80 hours, resulting in clinical effect up to 1 week after 24-hour infusion (29). More importantly, both aminophylline and dopamine improve contractility by elevating intracellular calcium concentration, resulting in an increased ATP utilization. As discussed elsewhere (12), inorganic phosphate accumulation contributes to the development of muscle fatigue and depresses calcium sensitivity (30). In addition, elevated energy expenditure increases CO2 production, requiring a higher level of ventilation. This limits the clinical utility of these drugs for the improvement of respiratory muscle function in patients with imminent ventilatory failure. Rather, calcium sensitizers improve muscle contractility without elevating energy expenditure (31). In addition, more effi-
cient breathing may hasten liberation from mechanical ventilation (32). This may be important for patients with respiratory failure, such as acute exacerbation of COPD. Of note, our previous in vitro work showed that the effect of levosimendan is more pro-
found in type-1 diaphragm fibers than in type-2 fibers (12). Be-

cause a fiber type shift toward type-1 fibers is known to occur in the diaphragm of patients with COPD (8) and congestive heart failure (33), levosimendan treatment can potentially be more effective in these patients than in healthy subjects. Accord-

ingly, the rationale for evaluating the effect of levosimendan on respiratory muscle function in patients with respiratory failure appears highly appropriate.

Experimental Model

The contractile performance of the diaphragm was evaluated using magnetic stimulation and maximal inspiratory efforts.

Figure 3. Percentage change in transdiaphragmatic twitch pressure (Pdiw) from baseline after loading + bolus administration in the placebo (closed squares) and levosimendan (open circles) group. Data are presented as mean ± SEM (placebo, n = 13; levosimendan, n = 14). *Significantly different from baseline (P = 0.01) and levosimendan group after loading + bolus administration (P = 0.01).
and thus increased neuromechanical efficiency of the diaphragm. The subject receiving levosimendan shows decreased neural activation relative to the placebo, there is no change in EMGdi (i.e., neural activation), whereas the subject receiving placebo shows decreased neural activation and thus increased neuromechanical efficiency of the diaphragm.

We also found that, despite evidence of twitch force loss, the diaphragm contractility with levosimendan. Moreover, levosimendan improved efficiency already during unloaded breathing and immediately at the start of the loading task, which is unlikely to be the result of improved oxygen delivery to the diaphragm.

The dosage of levosimendan used in the current study was derived from earlier studies in healthy subjects that demonstrated limited side effects (39). This is in line with our study. Future studies should evaluate the effects of lower doses of levosimendan on respiratory muscle function in humans.

In conclusion, the present study demonstrates that the calcium sensitizer levosimendan improves contractile function and neuromechanical efficiency of the human diaphragm. These findings suggest a new therapeutic approach for patients with acute respiratory muscle dysfunction.

**Author disclosures** are available with the text of this article at www.atsjournals.org.

**Acknowledgment:** The authors thank Dr. M. Kivikko and Prof. P. Byttila from Orion Pharma, Espoo, Finland, for providing levosimendan and placebo; N. Comtois from the Department of Medicine, Division of Critical Care Medicine, St. Michael’s Hospital, University of Toronto, Canada and Dr. H. van Dijk from the Department of Neurology, Radboud University Nijmegen Medical Centre, for technical assistance; J. van den Brule from the Department of Critical Care Medicine, Radboud University Nijmegen Medical Centre, for performing the transthoracic echocardiography; and the research nurses from the Department of Critical Care Medicine, Radboud University Nijmegen Medical Centre for assistance during the experiments.
References


